<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Anc Sci Life</journal-id><journal-id journal-id-type="iso-abbrev">Anc Sci Life</journal-id><journal-id journal-id-type="publisher-id">ASL</journal-id><journal-title-group><journal-title>Ancient Science of Life</journal-title></journal-title-group><issn pub-type="ppub">0257-7941</issn><issn pub-type="epub">2249-9547</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28867858</article-id><article-id pub-id-type="pmc">5566825</article-id><article-id pub-id-type="publisher-id">ASL-36-141</article-id><article-id pub-id-type="doi">10.4103/asl.ASL_8_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of Cyavanaprāśa on Health and Immunity related Parameters in Healthy Children: A Two Arm, Randomized, Open Labeled, Prospective, Multicenter, Clinical Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Arun</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Sunil</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Dole</surname><given-names>Sanjeeva</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Deshpande</surname><given-names>Shailesh</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Deshpande</surname><given-names>Vaishali</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Sudha</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Sasibhushan</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1"><italic>From the Dabur Research and Development Centre, Ghaziabad, Uttar Pradesh, India</italic></aff><aff id="aff2"><label>1</label><italic>Department of Kaumarbhrtya, Sumati Shah Ayurvedic Hospital, Pune, Maharashtra, India</italic></aff><aff id="aff3"><label>2</label><italic>PDEA's College of Ayurveda and Research Centre, Pune, Maharashtra, India</italic></aff><author-notes><corresp id="cor1"><bold><italic>Address for correspondence: </italic></bold><italic>Dr. Arun Gupta, Medical Affairs and Clinical Research Division, Dabur Research and Development Centre, Dabur India Limited, 22, Site IV, Sahibabad (Ghaziabad), Uttar Pradesh - 201 010, India. E-mail: <email xlink:href="arun.gupta@mail.dabur">arun.gupta@mail.dabur</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2017</year></pub-date><volume>36</volume><issue>3</issue><fpage>141</fpage><lpage>150</lpage><history><date date-type="received"><month>1</month><year>2017</year></date><date date-type="accepted"><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2017 Ancient Science of Life</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4095" xml_f="4103" txt_i="11" txt_f="19">Context:</offsets></title><p><offsets xml_i="4114" xml_f="4302" txt_i="20" txt_f="208">Cyavanaprāśa (CP) is an Ayurvedic immune booster formulation that confers vigor and vitality while delaying the ageing process. Benefits of CP have been studied widely in adult population.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4333" xml_f="4344" txt_i="210" txt_f="221">Objectives:</offsets></title><p><offsets xml_i="4355" xml_f="4465" txt_i="222" txt_f="332">Current study assessed beneficial effects of CP on health and immunity related parameters in healthy children.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4496" xml_f="4504" txt_i="334" txt_f="342">Methods:</offsets></title><p><offsets xml_i="4515" xml_f="5223" txt_i="343" txt_f="1051">This study was a 6 month long two armed, randomized, open labeled, prospective clinical study. School going healthy children between ages of 5-12 years were randomized to receive orally daily either CP (approx. 6 g) followed by a cup of milk (100 – 200 ml) or cup of milk only twice a day while continuing with their normal/routine diet. Results were analyzed based on number of episodes, severity, duration of illness (infections and allergies) and number of absent days due to illness during the study duration and changes in levels of energy, physical fitness, strength, stamina and quality of life in children which were recorded in subject diary by their parents/Legally Acceptable Representative (LAR).</offsets></p></sec><sec id="st4"><title><offsets xml_i="5254" xml_f="5262" txt_i="1053" txt_f="1061">Results:</offsets></title><p><offsets xml_i="5273" xml_f="5736" txt_i="1062" txt_f="1525">702 participants were randomized, out of which 627 completed the study (CP n = 313; Control n = 314). Results of immunity (episodes of infections or allergy related conditions) showed more than 2 times protection from immunity related illness in CP Group as compared to the control. CP also showed better percentage improvement in energy levels, physical fitness, strength, stamina and quality of life assessed through KIDSCREEN QOL-27 questionnaires in children.</offsets></p></sec><sec id="st5"><title><offsets xml_i="5767" xml_f="5778" txt_i="1527" txt_f="1538">Conclusion:</offsets></title><p><offsets xml_i="5789" xml_f="5984" txt_i="1539" txt_f="1734">Regular consumption of CP for a period of six months could significantly improve immunity, energy levels, physical fitness, strength, stamina and quality of life in school going healthy children.</offsets></p></sec><sec id="st6"><title><offsets xml_i="6015" xml_f="6034" txt_i="1736" txt_f="1755">Study Registration:</offsets></title><p><offsets xml_i="6045" xml_f="6078" txt_i="1756" txt_f="1789">Clinical Trail Registry of India </offsets><italic><offsets xml_i="6086" xml_f="6090" txt_i="1789" txt_f="1793">vide</offsets></italic><offsets xml_i="6099" xml_f="6144" txt_i="1793" txt_f="1838"> CTRI/2015/02/005574, Dated 24 February 2015.</offsets></p></sec></abstract><kwd-group><kwd><italic>Allergy</italic></kwd><kwd><italic>children</italic></kwd><kwd><italic>chyawanprash</italic></kwd><kwd><italic>immunity</italic></kwd><kwd><italic>infection</italic></kwd><kwd><italic>KIDSCREEN-27 questionnaire</italic></kwd><kwd><italic>strength</italic></kwd><kwd><italic>stamina</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="6567" xml_f="6579" txt_i="1847" txt_f="1859">Introduction</offsets></title><sec id="sec2-1"><title><offsets xml_i="6611" xml_f="6621" txt_i="1860" txt_f="1870">Background</offsets></title><p><offsets xml_i="6632" xml_f="6765" txt_i="1871" txt_f="2004">Children suffer from infections more than adults. On an average, a child suffers from four to eight respiratory infections per year.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6798" xml_f="6799" txt_i="2004" txt_f="2005">1</offsets></xref><offsets xml_i="6806" xml_f="7031" txt_i="2005" txt_f="2230">] This number varies depending on the presence or absence of risk factors that predispose to an increase in infective or allergic agents exposure; such as day-care attendance, school-aged siblings, and second-hand smoke etc.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="7064" xml_f="7065" txt_i="2230" txt_f="2231">2</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="7105" xml_f="7106" txt_i="2231" txt_f="2232">3</offsets></xref><offsets xml_i="7113" xml_f="7316" txt_i="2232" txt_f="2435">] Children with atopic disease seem more likely to develop recurrent and persistent upper respiratory infections probably due to enhanced adherence of micro-organisms to inflamed respiratory epithelium.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="7349" xml_f="7350" txt_i="2435" txt_f="2436">4</offsets></xref><offsets xml_i="7357" xml_f="7512" txt_i="2436" txt_f="2591">] It is estimated that consumers purchase about 95 million packages of OTC medication for cough and cold for use in such situations in children each year.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7545" xml_f="7546" txt_i="2591" txt_f="2592">5</offsets></xref><offsets xml_i="7553" xml_f="7554" txt_i="2592" txt_f="2593">]</offsets></p><p><offsets xml_i="7561" xml_f="7801" txt_i="2594" txt_f="2834">Cyavanaprāśa (CP) is an Ayurvedic health product that helps in boosting immunity. CP has been found to be effective as an immunity booster, vitalizer and a preventer of day to day infections and allergies such as common cold and cough etc.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7834" xml_f="7835" txt_i="2834" txt_f="2835">6</offsets></xref><offsets xml_i="7842" xml_f="7843" txt_i="2835" txt_f="2836">]</offsets></p><p><offsets xml_i="7850" xml_f="8119" txt_i="2837" txt_f="3106">In recent times, CP has gained immense popularity all over the world as a time tested immunity booster. CP can be consumed in all seasons as it contains weather friendly ingredients which nullify unpleasant effects due to extreme environmental and climatic conditions.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="8152" xml_f="8153" txt_i="3106" txt_f="3107">7</offsets></xref><offsets xml_i="8160" xml_f="8271" txt_i="3107" txt_f="3218">] Beneficial effects of CP have been observed in nasal allergies and viral infections and seasonal influences.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="8304" xml_f="8305" txt_i="3218" txt_f="3219">7</offsets></xref><xref rid="ref8" ref-type="bibr"><offsets xml_i="8345" xml_f="8346" txt_i="3219" txt_f="3220">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="8386" xml_f="8387" txt_i="3220" txt_f="3221">9</offsets></xref><offsets xml_i="8394" xml_f="8659" txt_i="3221" txt_f="3486">] There exists enough evidence suggesting its multifaceted biological activity in favor of positive health. Till now CP has been studied in diverse population and there is scarcity of documented data regarding its use in children, specially, school going children.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="8692" xml_f="8693" txt_i="3486" txt_f="3487">9</offsets></xref><offsets xml_i="8700" xml_f="8701" txt_i="3487" txt_f="3488">]</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="8735" xml_f="8744" txt_i="3490" txt_f="3499">Objective</offsets></title><p><offsets xml_i="8755" xml_f="8911" txt_i="3500" txt_f="3656">The current study was planned to study comprehensively the beneficial effects of CP in school going children for various immunity related health parameters.</offsets></p></sec></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="8970" xml_f="8977" txt_i="3659" txt_f="3666">Methods</offsets></title><sec id="sec2-3"><title><offsets xml_i="9009" xml_f="9021" txt_i="3667" txt_f="3679">Study design</offsets></title><p><offsets xml_i="9032" xml_f="9652" txt_i="3680" txt_f="4300">Current study was a 6 month long two arm, randomized, open labeled, prospective, clinical study conducted between Mar 2015 to Feb 2016 at two school sites in Maharashtra, India viz. Sane Guruji Vidya Mandir, Hadapsar and Shishuvihar pre-primary and primary school, Akrudi that were attached to Sumatibhai Shah Ayurvedic Hospital, Hadapsar and PDEA's College of Ayurveda and Research Center, Akrudi, respectively. The study was conducted in compliance with applicable ethical guidelines. Ethics committee approvals were obtained before study initiation. The Study was registered with the Clinical Trail Registry of India </offsets><italic><offsets xml_i="9660" xml_f="9664" txt_i="4300" txt_f="4304">vide</offsets></italic><offsets xml_i="9673" xml_f="9806" txt_i="4304" txt_f="4437"> CTRI/2015/02/005574, Dated 24 Feb 2015. The CONSORT statement guidelines have been followed in reporting the outcomes of the study.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="9840" xml_f="9842" txt_i="4437" txt_f="4439">10</offsets></xref><offsets xml_i="9849" xml_f="9850" txt_i="4439" txt_f="4440">]</offsets></p></sec><sec id="sec2-4"><title><offsets xml_i="9884" xml_f="9902" txt_i="4442" txt_f="4460">Study participants</offsets></title><p><offsets xml_i="9913" xml_f="10198" txt_i="4461" txt_f="4746">School going children of either sex were screened for eligibility (Day 3) and were recruited if they fulfilled the inclusion and exclusion criteria. Written informed consent was taken from parents/Legally Acceptable Representatives (LAR) along with participant assent where applicable.</offsets></p><sec id="sec3-1"><title><offsets xml_i="10226" xml_f="10244" txt_i="4747" txt_f="4765">Inclusion criteria</offsets></title><p><offsets xml_i="10255" xml_f="10473" txt_i="4766" txt_f="4984">Healthy children of either sex aged between 5-12 years, having no history of allergic conditions to CP like products or any ingredient of CP and who were not averse to consuming CP for the study duration were included.</offsets></p></sec><sec id="sec3-2"><title><offsets xml_i="10507" xml_f="10525" txt_i="4986" txt_f="5004">Exclusion criteria</offsets></title><p><offsets xml_i="10536" xml_f="10960" txt_i="5005" txt_f="5429">(i) Children with presence of any clinically significant medical or surgical condition requiring long-term treatment; (ii) subjects participating/having participated in another clinical study within 3 months before recruitment; (iii) evidence of significant uncontrolled concomitant disease which in the investigator's opinion would preclude patient participation and (iv) immunologically compromised children were excluded.</offsets></p></sec></sec><sec id="sec2-5"><title><offsets xml_i="11000" xml_f="11019" txt_i="5432" txt_f="5451">Study interventions</offsets></title><p><offsets xml_i="11030" xml_f="11111" txt_i="5452" txt_f="5533">Cyavanaprāśa is a classical Ayurvedic formulation comprising ingredients such as </offsets><italic><offsets xml_i="11119" xml_f="11125" txt_i="5533" txt_f="5539">Pāṭalā</offsets></italic><offsets xml_i="11134" xml_f="11136" txt_i="5539" txt_f="5541"> (</offsets><italic><offsets xml_i="11144" xml_f="11168" txt_i="5541" txt_f="5565">Stereospermum suaveolens</offsets></italic><offsets xml_i="11177" xml_f="11189" txt_i="5565" txt_f="5577">, St. Bk.), </offsets><italic><offsets xml_i="11197" xml_f="11207" txt_i="5577" txt_f="5587">Agnimantha</offsets></italic><offsets xml_i="11216" xml_f="11218" txt_i="5587" txt_f="5589"> (</offsets><italic><offsets xml_i="11226" xml_f="11248" txt_i="5589" txt_f="5611">Clerodendrum phlomidis</offsets></italic><offsets xml_i="11257" xml_f="11269" txt_i="5611" txt_f="5623">, St. Bk.), </offsets><italic><offsets xml_i="11277" xml_f="11285" txt_i="5623" txt_f="5631">Gambhārī</offsets></italic><offsets xml_i="11294" xml_f="11296" txt_i="5631" txt_f="5633"> (</offsets><italic><offsets xml_i="11304" xml_f="11319" txt_i="5633" txt_f="5648">Gmelina arborea</offsets></italic><offsets xml_i="11328" xml_f="11340" txt_i="5648" txt_f="5660">, St. Bk.), </offsets><italic><offsets xml_i="11348" xml_f="11353" txt_i="5660" txt_f="5665">Bilva</offsets></italic><offsets xml_i="11362" xml_f="11364" txt_i="5665" txt_f="5667"> (</offsets><italic><offsets xml_i="11372" xml_f="11386" txt_i="5667" txt_f="5681">Aegle marmelos</offsets></italic><offsets xml_i="11395" xml_f="11407" txt_i="5681" txt_f="5693">, St. Bk.), </offsets><italic><offsets xml_i="11415" xml_f="11422" txt_i="5693" txt_f="5700">Syonāka</offsets></italic><offsets xml_i="11431" xml_f="11433" txt_i="5700" txt_f="5702"> (</offsets><italic><offsets xml_i="11441" xml_f="11457" txt_i="5702" txt_f="5718">Oroxylum indicum</offsets></italic><offsets xml_i="11466" xml_f="11478" txt_i="5718" txt_f="5730">, St. Bk.), </offsets><italic><offsets xml_i="11486" xml_f="11493" txt_i="5730" txt_f="5737">Gokṣura</offsets></italic><offsets xml_i="11502" xml_f="11504" txt_i="5737" txt_f="5739"> (</offsets><italic><offsets xml_i="11512" xml_f="11531" txt_i="5739" txt_f="5758">Tribulus terrestris</offsets></italic><offsets xml_i="11540" xml_f="11548" txt_i="5758" txt_f="5766">, Fr.), </offsets><italic><offsets xml_i="11556" xml_f="11565" txt_i="5766" txt_f="5775">Śālaparṇī</offsets></italic><offsets xml_i="11574" xml_f="11576" txt_i="5775" txt_f="5777"> (</offsets><italic><offsets xml_i="11584" xml_f="11604" txt_i="5777" txt_f="5797">Desmodium gangeticum</offsets></italic><offsets xml_i="11613" xml_f="11621" txt_i="5797" txt_f="5805">, Pl.), </offsets><italic><offsets xml_i="11629" xml_f="11639" txt_i="5805" txt_f="5815">Prśṇiparṇī</offsets></italic><offsets xml_i="11648" xml_f="11650" txt_i="5815" txt_f="5817"> (</offsets><italic><offsets xml_i="11658" xml_f="11670" txt_i="5817" txt_f="5829">Uraria picta</offsets></italic><offsets xml_i="11679" xml_f="11687" txt_i="5829" txt_f="5837">, Pl.), </offsets><italic><offsets xml_i="11695" xml_f="11701" txt_i="5837" txt_f="5843">Bṛhatī</offsets></italic><offsets xml_i="11710" xml_f="11712" txt_i="5843" txt_f="5845"> (</offsets><italic><offsets xml_i="11720" xml_f="11735" txt_i="5845" txt_f="5860">Solanum indicum</offsets></italic><offsets xml_i="11744" xml_f="11752" txt_i="5860" txt_f="5868">, Pl.), </offsets><italic><offsets xml_i="11760" xml_f="11769" txt_i="5868" txt_f="5877">Kaṇṭakārī</offsets></italic><offsets xml_i="11778" xml_f="11780" txt_i="5877" txt_f="5879"> (</offsets><italic><offsets xml_i="11788" xml_f="11806" txt_i="5879" txt_f="5897">Solanum surattense</offsets></italic><offsets xml_i="11815" xml_f="11823" txt_i="5897" txt_f="5905">, Pl.), </offsets><italic><offsets xml_i="11831" xml_f="11838" txt_i="5905" txt_f="5912">Pippalī</offsets></italic><offsets xml_i="11847" xml_f="11849" txt_i="5912" txt_f="5914"> (</offsets><italic><offsets xml_i="11857" xml_f="11869" txt_i="5914" txt_f="5926">Piper longum</offsets></italic><offsets xml_i="11878" xml_f="11886" txt_i="5926" txt_f="5934">, Fr.), </offsets><italic><offsets xml_i="11894" xml_f="11906" txt_i="5934" txt_f="5946">Karkaṭaśṛṅgī</offsets></italic><offsets xml_i="11915" xml_f="11917" txt_i="5946" txt_f="5948"> (</offsets><italic><offsets xml_i="11925" xml_f="11945" txt_i="5948" txt_f="5968">Pistacia integerrima</offsets></italic><offsets xml_i="11954" xml_f="11962" txt_i="5968" txt_f="5976">, Gl.), </offsets><italic><offsets xml_i="11970" xml_f="11976" txt_i="5976" txt_f="5982">Drākṣā</offsets></italic><offsets xml_i="11985" xml_f="11987" txt_i="5982" txt_f="5984"> (</offsets><italic><offsets xml_i="11995" xml_f="12009" txt_i="5984" txt_f="5998">Vitis vinifera</offsets></italic><offsets xml_i="12018" xml_f="12026" txt_i="5998" txt_f="6006">, Fr.), </offsets><italic><offsets xml_i="12034" xml_f="12040" txt_i="6006" txt_f="6012">Guḍūcī</offsets></italic><offsets xml_i="12049" xml_f="12051" txt_i="6012" txt_f="6014"> (</offsets><italic><offsets xml_i="12059" xml_f="12079" txt_i="6014" txt_f="6034">Tinospora cordifolia</offsets></italic><offsets xml_i="12088" xml_f="12096" txt_i="6034" txt_f="6042">, St.), </offsets><italic><offsets xml_i="12104" xml_f="12112" txt_i="6042" txt_f="6050">Harītakī</offsets></italic><offsets xml_i="12121" xml_f="12123" txt_i="6050" txt_f="6052"> (</offsets><italic><offsets xml_i="12131" xml_f="12149" txt_i="6052" txt_f="6070">Terminalia chebula</offsets></italic><offsets xml_i="12158" xml_f="12165" txt_i="6070" txt_f="6077">, P.), </offsets><italic><offsets xml_i="12173" xml_f="12177" txt_i="6077" txt_f="6081">Balā</offsets></italic><offsets xml_i="12186" xml_f="12188" txt_i="6081" txt_f="6083"> (</offsets><italic><offsets xml_i="12196" xml_f="12211" txt_i="6083" txt_f="6098">Sida cordifolia</offsets></italic><offsets xml_i="12220" xml_f="12228" txt_i="6098" txt_f="6106">, Rt.), </offsets><italic><offsets xml_i="12236" xml_f="12244" txt_i="6106" txt_f="6114">Tāmalakī</offsets></italic><offsets xml_i="12253" xml_f="12255" txt_i="6114" txt_f="6116"> (</offsets><italic><offsets xml_i="12263" xml_f="12281" txt_i="6116" txt_f="6134">Phyllanthus niruri</offsets></italic><offsets xml_i="12290" xml_f="12298" txt_i="6134" txt_f="6142">, Pl.), </offsets><italic><offsets xml_i="12306" xml_f="12310" txt_i="6142" txt_f="6146">Vasā</offsets></italic><offsets xml_i="12319" xml_f="12321" txt_i="6146" txt_f="6148"> (</offsets><italic><offsets xml_i="12329" xml_f="12344" txt_i="6148" txt_f="6163">Adhatoda vasica</offsets></italic><offsets xml_i="12353" xml_f="12361" txt_i="6163" txt_f="6171">, Lf.), </offsets><italic><offsets xml_i="12369" xml_f="12376" txt_i="6171" txt_f="6178">Jīvantī</offsets></italic><offsets xml_i="12385" xml_f="12387" txt_i="6178" txt_f="6180"> (</offsets><italic><offsets xml_i="12395" xml_f="12416" txt_i="6180" txt_f="6201">Leptadenia reticulata</offsets></italic><offsets xml_i="12425" xml_f="12433" txt_i="6201" txt_f="6209">, Pl.), </offsets><italic><offsets xml_i="12441" xml_f="12446" txt_i="6209" txt_f="6214">Shaṭī</offsets></italic><offsets xml_i="12455" xml_f="12457" txt_i="6214" txt_f="6216"> (</offsets><italic><offsets xml_i="12465" xml_f="12483" txt_i="6216" txt_f="6234">Heydichum spicatum</offsets></italic><offsets xml_i="12492" xml_f="12500" txt_i="6234" txt_f="6242">, Rz.), </offsets><italic><offsets xml_i="12508" xml_f="12513" txt_i="6242" txt_f="6247">Mustā</offsets></italic><offsets xml_i="12522" xml_f="12524" txt_i="6247" txt_f="6249"> (</offsets><italic><offsets xml_i="12532" xml_f="12548" txt_i="6249" txt_f="6265">Cyperus rotundus</offsets></italic><offsets xml_i="12557" xml_f="12565" txt_i="6265" txt_f="6273">, Rz.), </offsets><italic><offsets xml_i="12573" xml_f="12580" txt_i="6273" txt_f="6280">Puṣkara</offsets></italic><offsets xml_i="12589" xml_f="12591" txt_i="6280" txt_f="6282"> (</offsets><italic><offsets xml_i="12599" xml_f="12613" txt_i="6282" txt_f="6296">Inula racemosa</offsets></italic><offsets xml_i="12622" xml_f="12630" txt_i="6296" txt_f="6304">, Rt.), </offsets><italic><offsets xml_i="12638" xml_f="12648" txt_i="6304" txt_f="6314">Kākanāsikā</offsets></italic><offsets xml_i="12657" xml_f="12659" txt_i="6314" txt_f="6316"> (</offsets><italic><offsets xml_i="12667" xml_f="12681" txt_i="6316" txt_f="6330">Martynia annua</offsets></italic><offsets xml_i="12690" xml_f="12698" txt_i="6330" txt_f="6338">, Ft.), </offsets><italic><offsets xml_i="12706" xml_f="12716" txt_i="6338" txt_f="6348">Mudgaparṇī</offsets></italic><offsets xml_i="12725" xml_f="12727" txt_i="6348" txt_f="6350"> (</offsets><italic><offsets xml_i="12735" xml_f="12753" txt_i="6350" txt_f="6368">Phaseolus trilobus</offsets></italic><offsets xml_i="12762" xml_f="12770" txt_i="6368" txt_f="6376">, Pl.), </offsets><italic><offsets xml_i="12778" xml_f="12787" txt_i="6376" txt_f="6385">Māṣaparṇī</offsets></italic><offsets xml_i="12796" xml_f="12798" txt_i="6385" txt_f="6387"> (</offsets><italic><offsets xml_i="12806" xml_f="12823" txt_i="6387" txt_f="6404">Teramnus labialis</offsets></italic><offsets xml_i="12832" xml_f="12840" txt_i="6404" txt_f="6412">, Pl.), </offsets><italic><offsets xml_i="12848" xml_f="12857" txt_i="6412" txt_f="6421">Punarnavā</offsets></italic><offsets xml_i="12866" xml_f="12868" txt_i="6421" txt_f="6423"> (</offsets><italic><offsets xml_i="12876" xml_f="12893" txt_i="6423" txt_f="6440">Boerhavia diffusa</offsets></italic><offsets xml_i="12902" xml_f="12910" txt_i="6440" txt_f="6448">, Rt.), </offsets><italic><offsets xml_i="12918" xml_f="12924" txt_i="6448" txt_f="6454">Utpala</offsets></italic><offsets xml_i="12933" xml_f="12935" txt_i="6454" txt_f="6456"> (</offsets><italic><offsets xml_i="12943" xml_f="12960" txt_i="6456" txt_f="6473">Nymphaea stellata</offsets></italic><offsets xml_i="12969" xml_f="12977" txt_i="6473" txt_f="6481">, Fl.), </offsets><italic><offsets xml_i="12985" xml_f="12994" txt_i="6481" txt_f="6490">Sūkṣmaila</offsets></italic><offsets xml_i="13003" xml_f="13005" txt_i="6490" txt_f="6492"> (</offsets><italic><offsets xml_i="13013" xml_f="13033" txt_i="6492" txt_f="6512">Elettaria cardamomum</offsets></italic><offsets xml_i="13042" xml_f="13053" txt_i="6512" txt_f="6523">, Sd., Ft. </offsets><italic><offsets xml_i="13061" xml_f="13065" txt_i="6523" txt_f="6527">Tvak</offsets></italic><offsets xml_i="13074" xml_f="13076" txt_i="6527" txt_f="6529"> (</offsets><italic><offsets xml_i="13084" xml_f="13105" txt_i="6529" txt_f="6550">Cinnamomum zeylanicum</offsets></italic><offsets xml_i="13114" xml_f="13122" txt_i="6550" txt_f="6558">, Bk.), </offsets><italic><offsets xml_i="13130" xml_f="13137" txt_i="6558" txt_f="6565">Candana</offsets></italic><offsets xml_i="13146" xml_f="13147" txt_i="6565" txt_f="6566">
</offsets><italic><offsets xml_i="13155" xml_f="13160" txt_i="6566" txt_f="6571">Śveta</offsets></italic><offsets xml_i="13169" xml_f="13171" txt_i="6571" txt_f="6573"> (</offsets><italic><offsets xml_i="13179" xml_f="13193" txt_i="6573" txt_f="6587">Santalum album</offsets></italic><offsets xml_i="13202" xml_f="13214" txt_i="6587" txt_f="6599">, Ht. wd.), </offsets><italic><offsets xml_i="13222" xml_f="13228" txt_i="6599" txt_f="6605">Vārāhī</offsets></italic><offsets xml_i="13237" xml_f="13239" txt_i="6605" txt_f="6607"> (</offsets><italic><offsets xml_i="13247" xml_f="13266" txt_i="6607" txt_f="6626">Dioscorea bulbifera</offsets></italic><offsets xml_i="13275" xml_f="13287" txt_i="6626" txt_f="6638">, Rt. Tr.), </offsets><italic><offsets xml_i="13295" xml_f="13303" txt_i="6638" txt_f="6646">Śatāvarī</offsets></italic><offsets xml_i="13312" xml_f="13314" txt_i="6646" txt_f="6648"> (</offsets><italic><offsets xml_i="13322" xml_f="13341" txt_i="6648" txt_f="6667">Asparagus racemosus</offsets></italic><offsets xml_i="13350" xml_f="13358" txt_i="6667" txt_f="6675">, Rt.), </offsets><italic><offsets xml_i="13366" xml_f="13376" txt_i="6675" txt_f="6685">Aśvagandhā</offsets></italic><offsets xml_i="13385" xml_f="13387" txt_i="6685" txt_f="6687"> (</offsets><italic><offsets xml_i="13395" xml_f="13413" txt_i="6687" txt_f="6705">Withania somnifera</offsets></italic><offsets xml_i="13422" xml_f="13430" txt_i="6705" txt_f="6713">, Rt.), </offsets><italic><offsets xml_i="13438" xml_f="13444" txt_i="6713" txt_f="6719">Vidārī</offsets></italic><offsets xml_i="13453" xml_f="13455" txt_i="6719" txt_f="6721"> (</offsets><italic><offsets xml_i="13463" xml_f="13480" txt_i="6721" txt_f="6738">Pueraria tuberosa</offsets></italic><offsets xml_i="13489" xml_f="13501" txt_i="6738" txt_f="6750">, Rt. Tr.), </offsets><italic><offsets xml_i="13509" xml_f="13516" txt_i="6750" txt_f="6757">Āmalakī</offsets></italic><offsets xml_i="13525" xml_f="13527" txt_i="6757" txt_f="6759"> (</offsets><italic><offsets xml_i="13535" xml_f="13554" txt_i="6759" txt_f="6778">Emblica officinalis</offsets></italic><offsets xml_i="13563" xml_f="13571" txt_i="6778" txt_f="6786">, Fr.), </offsets><italic><offsets xml_i="13579" xml_f="13584" txt_i="6786" txt_f="6791">Ghṛta</offsets></italic><offsets xml_i="13593" xml_f="13614" txt_i="6791" txt_f="6812"> (Clarified butter), </offsets><italic><offsets xml_i="13622" xml_f="13626" txt_i="6812" txt_f="6816">Tila</offsets></italic><offsets xml_i="13635" xml_f="13636" txt_i="6816" txt_f="6817">
</offsets><italic><offsets xml_i="13644" xml_f="13649" txt_i="6817" txt_f="6822">taila</offsets></italic><offsets xml_i="13658" xml_f="13660" txt_i="6822" txt_f="6824"> (</offsets><italic><offsets xml_i="13668" xml_f="13683" txt_i="6824" txt_f="6839">Sesamum indicum</offsets></italic><offsets xml_i="13692" xml_f="13700" txt_i="6839" txt_f="6847">, oil), </offsets><italic><offsets xml_i="13708" xml_f="13715" txt_i="6847" txt_f="6854">Śarkara</offsets></italic><offsets xml_i="13724" xml_f="13742" txt_i="6854" txt_f="6872"> (Crystal sugar), </offsets><italic><offsets xml_i="13750" xml_f="13755" txt_i="6872" txt_f="6877">Madhu</offsets></italic><offsets xml_i="13764" xml_f="13774" txt_i="6877" txt_f="6887"> (Honey), </offsets><italic><offsets xml_i="13782" xml_f="13789" txt_i="6887" txt_f="6894">Pippalī</offsets></italic><offsets xml_i="13798" xml_f="13800" txt_i="6894" txt_f="6896"> (</offsets><italic><offsets xml_i="13808" xml_f="13820" txt_i="6896" txt_f="6908">Piper longum</offsets></italic><offsets xml_i="13829" xml_f="13837" txt_i="6908" txt_f="6916">, Fr.), </offsets><italic><offsets xml_i="13845" xml_f="13850" txt_i="6916" txt_f="6921">Vamśa</offsets></italic><offsets xml_i="13859" xml_f="13861" txt_i="6921" txt_f="6923"> (</offsets><italic><offsets xml_i="13869" xml_f="13883" txt_i="6923" txt_f="6937">Bambusa bambos</offsets></italic><offsets xml_i="13892" xml_f="13901" txt_i="6937" txt_f="6946">, S.C.), </offsets><italic><offsets xml_i="13909" xml_f="13918" txt_i="6946" txt_f="6955">Tvakpatra</offsets></italic><offsets xml_i="13927" xml_f="13929" txt_i="6955" txt_f="6957"> (</offsets><italic><offsets xml_i="13937" xml_f="13954" txt_i="6957" txt_f="6974">Cinnamomum tamala</offsets></italic><offsets xml_i="13963" xml_f="13971" txt_i="6974" txt_f="6982">, lf.), </offsets><italic><offsets xml_i="13979" xml_f="13989" txt_i="6982" txt_f="6992">Nāgakesara</offsets></italic><offsets xml_i="13998" xml_f="14000" txt_i="6992" txt_f="6994"> (</offsets><italic><offsets xml_i="14008" xml_f="14020" txt_i="6994" txt_f="7006">Mesua ferrea</offsets></italic><offsets xml_i="14029" xml_f="14039" txt_i="7006" txt_f="7016">, Stmn.), </offsets><italic><offsets xml_i="14047" xml_f="14054" txt_i="7016" txt_f="7023">Abhraka</offsets></italic><offsets xml_i="14063" xml_f="14064" txt_i="7023" txt_f="7024">
</offsets><italic><offsets xml_i="14072" xml_f="14078" txt_i="7024" txt_f="7030">Bhasma</offsets></italic><offsets xml_i="14087" xml_f="14105" txt_i="7030" txt_f="7048"> (Calcined mica), </offsets><italic><offsets xml_i="14113" xml_f="14118" txt_i="7048" txt_f="7053">Muktā</offsets></italic><offsets xml_i="14127" xml_f="14128" txt_i="7053" txt_f="7054">
</offsets><italic><offsets xml_i="14136" xml_f="14141" txt_i="7054" txt_f="7059">Piṣṭi</offsets></italic><offsets xml_i="14150" xml_f="14179" txt_i="7059" txt_f="7088"> (Anhydrous paste of pearl), </offsets><italic><offsets xml_i="14187" xml_f="14199" txt_i="7088" txt_f="7100">Akarakarabha</offsets></italic><offsets xml_i="14208" xml_f="14210" txt_i="7100" txt_f="7102"> (</offsets><italic><offsets xml_i="14218" xml_f="14237" txt_i="7102" txt_f="7121">Anacyclus pyrethrum</offsets></italic><offsets xml_i="14246" xml_f="14254" txt_i="7121" txt_f="7129">, Rt.), </offsets><italic><offsets xml_i="14262" xml_f="14269" txt_i="7129" txt_f="7136">Lavaṅga</offsets></italic><offsets xml_i="14278" xml_f="14280" txt_i="7136" txt_f="7138"> (</offsets><italic><offsets xml_i="14288" xml_f="14307" txt_i="7138" txt_f="7157">Syzygium aromaticum</offsets></italic><offsets xml_i="14316" xml_f="14327" txt_i="7157" txt_f="7168">, Fl.Bd.), </offsets><italic><offsets xml_i="14335" xml_f="14342" txt_i="7168" txt_f="7175">Kuṅkuma</offsets></italic><offsets xml_i="14351" xml_f="14353" txt_i="7175" txt_f="7177"> (</offsets><italic><offsets xml_i="14361" xml_f="14375" txt_i="7177" txt_f="7191">Crocus sativus</offsets></italic><offsets xml_i="14384" xml_f="14500" txt_i="7191" txt_f="7307">, sty./stg.). In the current study, Cyavanaprāśa (Mfd: Dabur India Ltd.) manufactured following traditional methods[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="14534" xml_f="14536" txt_i="7307" txt_f="7309">11</offsets></xref><offsets xml_i="14543" xml_f="14762" txt_i="7309" txt_f="7528">] was used. The proximate analysis of CP showed Moisture content- 18.0—23.0% w/w, Total Fat- 1.5—2.5% w/w, Protein- Not detected, Dietary Fibre- 2.0—3.0% w/w, Total Ash- 3.0—5.0% w/w, Total Carbohydrate- 70.0—80.0% w/w.</offsets></p></sec><sec id="sec2-6"><title><offsets xml_i="14796" xml_f="14811" txt_i="7530" txt_f="7545">Study procedure</offsets></title><p><offsets xml_i="14822" xml_f="15433" txt_i="7546" txt_f="8157">At screening/baseline visit, a parent- teacher meeting was conducted to brief parents/LAR about study requirements and their written informed consent was obtained after one to one session with them. Assent for participation in the study was also obtained from participant, if applicable. Participants’ physical and systemic examinations were done and vitals were recorded. Parents/LAR were handed over a subject diary and were trained to record episodes of illness (number of episodes, severity and duration of infection/allergies for assessment of immunity) and the KIDSCREEN QOL-27 Health Questionnaire in it.</offsets></p><p><offsets xml_i="15440" xml_f="16185" txt_i="8158" txt_f="8903">Recruited children were assigned to either CP group or Milk Group as per computer generated randomization list in 1:1 ratio. Children in CP Group were provided 500 gm jar of CP and parents/LAR were asked to give their child half a teaspoon (approx. 6 gm) of CP orally two times followed by a cup of milk daily. Parents in Milk group were asked to give their child a cup of milk only twice daily. The cup of milk was considered to be between 100-200 ml. Both the interventions were prescribed for a period for 6 months; during which, participants in both the groups were advised to continue with their normal/routine diet. A record of the children who were absent during the treatment period was observed and the reason for the same was recorded.</offsets></p></sec><sec id="sec2-7"><title><offsets xml_i="16219" xml_f="16256" txt_i="8905" txt_f="8942">Follow up and end of study assessment</offsets></title><p><offsets xml_i="16267" xml_f="16865" txt_i="8943" txt_f="9541">Participants were followed up for 6 months from baseline on Day 30, 60, 90, 120, 150 and 180 (±7 d). Last participant follow up was observed in the month of Feb 2016. At each follow-up visit, filled in questionnaires/scales were collected, study drug compliance was checked and CP supply was replenished as applicable. If 80% study medication was consumed over 80% time, the participant was considered compliant. Parents/LAR were enquired for any adverse event (s). At the end of the study, Parents/LAR were asked to stop giving CP and take the advice of investigator for further treatment, if any.</offsets></p></sec><sec id="sec2-8"><title><offsets xml_i="16899" xml_f="16907" txt_i="9543" txt_f="9551">Outcomes</offsets></title><p><offsets xml_i="16918" xml_f="17124" txt_i="9552" txt_f="9758">The primary outcome of the study was the assessment of immunity through episodes, severity and duration of immunity related illness (infections or allergies) in both study groups based on the subject diary.</offsets></p><p><offsets xml_i="17131" xml_f="17856" txt_i="9759" txt_f="10484">The secondary outcomes of the study were assessment of immunity through number of children having episode of immunity related illness; number of absent days and number of children absent from school due infection or allergy; children's Quality of life was evaluated using KIDSCREEN QOL-27 Health Questionnaires for Children. Their energy levels, physical fitness, strength and stamina; physician's global evaluation for overall improvement on CGI-I Scale; incidence of adverse events, serious adverse events and vitals during the study period; overall safety and tolerability by the physician and participant/parent was evaluated at the end of the study. Prakṛti evaluation was also conducted at the screening/baseline visit.</offsets></p><p><offsets xml_i="17863" xml_f="18158" txt_i="10485" txt_f="10780">Levels of Energy, physical strength, stamina and, the physical fitness were measured on a 7-point scale ranging from +3 to -3 [-3 (very dissatisfied), -2 (somewhat dissatisfied), -1 (a little dissatisfied), 0 (neutral), +1 (a little satisfied), +2 (somewhat satisfied), and +3 (very satisfied)].</offsets></p><p><offsets xml_i="18165" xml_f="18433" txt_i="10781" txt_f="11049">KIDSCREEN QOL-27 Health Questionnaires were scored based on the scale ranging from 1 to 5 (1 - Excellent, 2 - Very Good, 3 - Good, 4 -Fair, 5- Poor; 1 - Not at all, 2 - Slightly, 3 - Moderately, 4 - Very, 5 - Extremely) depending on the response of the questionnaire).</offsets></p></sec><sec id="sec2-9"><title><offsets xml_i="18467" xml_f="18487" txt_i="11051" txt_f="11071">Statistical analysis</offsets></title><p><offsets xml_i="18498" xml_f="18908" txt_i="11072" txt_f="11482">The primary population for this study was Per-Protocol population. With more than 300 participants in each group, the sample size was considered sufficient for analysis. The primary efficacy endpoints were analyzed using two proportion test. A 95% confidence interval was constructed for the proportion. All secondary outcomes were analyzed by applying appropriate statistical methods such as proportion test, </offsets><italic><offsets xml_i="18916" xml_f="18917" txt_i="11482" txt_f="11483">t</offsets></italic><offsets xml_i="18926" xml_f="18936" txt_i="11483" txt_f="11493">-test etc.</offsets></p></sec></sec><sec id="sec1-3"><title><offsets xml_i="18976" xml_f="19000" txt_i="11496" txt_f="11520">Results and Observations</offsets></title><p><offsets xml_i="19011" xml_f="19541" txt_i="11521" txt_f="12051">A total of 703 school going children were screened in the study of which one was a screen failure and 702 were randomized. Of the 702 participants, there were 75 dropouts while 627 participants completed the study. Drop out reasons included (i) withdrawal of consent, (ii) Investigational Product (IP) taste dislike, (iii) lost to follow-up, (iv) change of school due to shifting of home to a different place or job transfer of parent to a far away place from current location etc., None of the drop-outs was due to adverse event.</offsets></p><p><offsets xml_i="19548" xml_f="20190" txt_i="12052" txt_f="12694">Out of the participants who completed the study, 313 participants were in CP Group and 314 were in Control Group. There were a total of 325 males (51.83%) and 302 females (48.16%). Of the 325 males, 161 (51.43%) were in CP group while 164 (52.22%) were in the control group while out of the 302 females, 152 (48.56%) were in the CP group while 150 (47.77%) were in the control group. Only those participants who completed the total study duration were included in the analysis. The average age of participants in the CP group was 7.31 ± 1.75 while in the control group it was 7.36 ± 1.80. The participant flow chart for the study is shown in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="20220" xml_f="20228" txt_i="12694" txt_f="12702">Figure 1</offsets></xref><offsets xml_i="20235" xml_f="20236" txt_i="12702" txt_f="12703">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="20277" xml_f="20285" txt_i="12704" txt_f="12712">Figure 1</offsets></label><caption><p><offsets xml_i="20305" xml_f="20361" txt_i="12712" txt_f="12768">Patient enrollment flow chart: CONSORT 2010 flow diagram</offsets></p></caption><graphic xlink:href="ASL-36-141-g001"></graphic></fig><p><offsets xml_i="20432" xml_f="20436" txt_i="12769" txt_f="12773">The </offsets><italic><offsets xml_i="20444" xml_f="20451" txt_i="12773" txt_f="12780">Prakṛti</offsets></italic><offsets xml_i="20460" xml_f="20507" txt_i="12780" txt_f="12827"> wise distribution of participants is shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="20539" xml_f="20546" txt_i="12827" txt_f="12834">Table 1</offsets></xref><offsets xml_i="20553" xml_f="20646" txt_i="12834" txt_f="12927">. It was observed that a majority of participants in both the groups were in the category of </offsets><italic><offsets xml_i="20654" xml_f="20665" txt_i="12927" txt_f="12938">pitta-kapha</offsets></italic><offsets xml_i="20674" xml_f="20676" txt_i="12938" txt_f="12940">, </offsets><italic><offsets xml_i="20684" xml_f="20689" txt_i="12940" txt_f="12945">pitta</offsets></italic><offsets xml_i="20698" xml_f="20699" txt_i="12945" txt_f="12946">-</offsets><italic><offsets xml_i="20707" xml_f="20711" txt_i="12946" txt_f="12950">vāta</offsets></italic><offsets xml_i="20720" xml_f="20725" txt_i="12950" txt_f="12955"> and </offsets><italic><offsets xml_i="20733" xml_f="20738" txt_i="12955" txt_f="12960">kapha</offsets></italic><offsets xml_i="20747" xml_f="20748" txt_i="12960" txt_f="12961">-</offsets><italic><offsets xml_i="20756" xml_f="20761" txt_i="12961" txt_f="12966">pitta</offsets></italic><offsets xml_i="20770" xml_f="20771" txt_i="12966" txt_f="12967">
</offsets><italic><offsets xml_i="20779" xml_f="20786" txt_i="12967" txt_f="12974">prakṛti</offsets></italic><offsets xml_i="20795" xml_f="20961" txt_i="12974" txt_f="13140">. There were 281 participants (89.77%) belonging to these phenotypes in CP group while in the control group; there were 284 participants (90.44%) of these phenotypes.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="21009" xml_f="21016" txt_i="13141" txt_f="13148">Table 1</offsets></label><caption><p><italic><offsets xml_i="21044" xml_f="21051" txt_i="13148" txt_f="13155">Prakṛti</offsets></italic><offsets xml_i="21060" xml_f="21112" txt_i="13155" txt_f="13207"> wise distribution of participants in the two groups</offsets></p></caption><graphic xlink:href="ASL-36-141-g002"></graphic></table-wrap><sec id="sec2-10"><title><offsets xml_i="21212" xml_f="21231" txt_i="13208" txt_f="13227">Efficacy parameters</offsets></title><p><offsets xml_i="21242" xml_f="21400" txt_i="13228" txt_f="13386">Primary and secondary outcomes of current study were observed in term of episodes of infection or allergy which were further divided into various categories [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="21432" xml_f="21439" txt_i="13386" txt_f="13393">Table 2</offsets></xref><offsets xml_i="21446" xml_f="21448" txt_i="13393" txt_f="13395">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="21496" xml_f="21503" txt_i="13396" txt_f="13403">Table 2</offsets></label><caption><p><offsets xml_i="21523" xml_f="21598" txt_i="13403" txt_f="13478">Infection/allergy related disorders observed in the study in the two groups</offsets></p></caption><graphic xlink:href="ASL-36-141-g003"></graphic></table-wrap><sec id="sec3-3"><title><offsets xml_i="21697" xml_f="21738" txt_i="13479" txt_f="13520">Assessment of immunity related parameters</offsets></title><p><offsets xml_i="21749" xml_f="21795" txt_i="13521" txt_f="13567">Assessment of episodes of infection or allergy</offsets></p><p><offsets xml_i="21802" xml_f="22030" txt_i="13568" txt_f="13796">A total of 1255 episodes related to infection or allergy were recorded in the study. Of these, 404 episodes (32.19%) were in CP group while 851 (67.80%) were in control group, which was assessed to be statistically significant (</offsets><italic><offsets xml_i="22038" xml_f="22039" txt_i="13796" txt_f="13797">P</offsets></italic><offsets xml_i="22048" xml_f="22157" txt_i="13797" txt_f="13903"> &lt; 0.001) and the proportionate difference was more than 2 times (2.10) when compared between the groups [</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="22187" xml_f="22195" txt_i="13903" txt_f="13911">Figure 2</offsets></xref><offsets xml_i="22202" xml_f="22204" txt_i="13911" txt_f="13913">].</offsets></p><fig id="F2" position="float"><label><offsets xml_i="22245" xml_f="22253" txt_i="13914" txt_f="13922">Figure 2</offsets></label><caption><p><offsets xml_i="22273" xml_f="22331" txt_i="13922" txt_f="13980">Number of episodes of illness related to infection/allergy</offsets></p></caption><graphic xlink:href="ASL-36-141-g004"></graphic></fig><p><offsets xml_i="22402" xml_f="22459" txt_i="13981" txt_f="14038">Evaluation of total duration of and severity of illnesses</offsets></p><p><offsets xml_i="22466" xml_f="22762" txt_i="14039" txt_f="14335">Evaluation of total duration of illnesses related to infection and allergy showed that of the total duration of 3983 days of illness, there were 1369 (34.37%) illness days in CP group whereas it was 2614 (65.62%) days in the control group. This difference was observed statistically significant (</offsets><italic><offsets xml_i="22770" xml_f="22771" txt_i="14335" txt_f="14336">P</offsets></italic><offsets xml_i="22780" xml_f="22851" txt_i="14336" txt_f="14404"> &lt; 0.01) and the proportionate difference was about 2 times (1.91) [</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="22881" xml_f="22889" txt_i="14404" txt_f="14412">Figure 3</offsets></xref><offsets xml_i="22896" xml_f="23093" txt_i="14412" txt_f="14609">]. A proportionate difference of 1.25 to 2.37 fold were observed between CP and control group while assessing episodes and duration of illness related to infection or allergy in terms of severity [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="23125" xml_f="23132" txt_i="14609" txt_f="14616">Table 3</offsets></xref><offsets xml_i="23139" xml_f="23141" txt_i="14616" txt_f="14618">].</offsets></p><fig id="F3" position="float"><label><offsets xml_i="23182" xml_f="23190" txt_i="14619" txt_f="14627">Figure 3</offsets></label><caption><p><offsets xml_i="23210" xml_f="23258" txt_i="14627" txt_f="14675">Duration of illness related to infection/allergy</offsets></p></caption><graphic xlink:href="ASL-36-141-g005"></graphic></fig><table-wrap id="T3" position="float"><label><offsets xml_i="23370" xml_f="23377" txt_i="14676" txt_f="14683">Table 3</offsets></label><caption><p><offsets xml_i="23397" xml_f="23490" txt_i="14683" txt_f="14776">Assessment of episodes and duration of illness related to infection/allergy based on severity</offsets></p></caption><graphic xlink:href="ASL-36-141-g006"></graphic></table-wrap><p><offsets xml_i="23568" xml_f="23641" txt_i="14777" txt_f="14850">Assessment of number of participants having episodes of infection/allergy</offsets></p><p><offsets xml_i="23648" xml_f="23902" txt_i="14851" txt_f="15105">A total of 540 participants had episodes of infection/allergy related to immunity. Of these, 254 participants (47.03%) participants were in CP group while 286 (52.96%) were in the control group. The difference observed was statistically not significant (</offsets><italic><offsets xml_i="23910" xml_f="23911" txt_i="15105" txt_f="15106">P</offsets></italic><offsets xml_i="23920" xml_f="24153" txt_i="15106" txt_f="15336"> &gt; 0.05). 87 participants did not have any episode related to infection/allergy. Of these, 60 participants (68.96%) were in CP group while 27 (31.03%) participants were control group. The difference was statistically significant (</offsets><italic><offsets xml_i="24161" xml_f="24162" txt_i="15336" txt_f="15337">P</offsets></italic><offsets xml_i="24171" xml_f="24183" txt_i="15337" txt_f="15346"> &lt; 0.01).</offsets></p><p><offsets xml_i="24190" xml_f="24229" txt_i="15347" txt_f="15386">Absenteeism due to infection or allergy</offsets></p><p><italic><offsets xml_i="24244" xml_f="24267" txt_i="15387" txt_f="15410">Numbers of absent days:</offsets></italic><offsets xml_i="24276" xml_f="24489" txt_i="15410" txt_f="15623"> There were a total of 702 absent days in 627 participants. Of these, 215 days (30.62%) were in CP group while 487 (69.37%) were in the control group. This difference was observed to be statistically significant (</offsets><italic><offsets xml_i="24497" xml_f="24498" txt_i="15623" txt_f="15624">P</offsets></italic><offsets xml_i="24507" xml_f="24521" txt_i="15624" txt_f="15635"> &lt; 0.001) [</offsets><xref ref-type="fig" rid="F4"><offsets xml_i="24551" xml_f="24559" txt_i="15635" txt_f="15643">Figure 4</offsets></xref><offsets xml_i="24566" xml_f="24834" txt_i="15643" txt_f="15911">]. There were a total of 281 participants who were absent due to infection/allergy/immunity related illnesses. Of these, 93 participants (33.09%) were in CP group while 188 (66.90%) were in the control group. This difference was found to be statistically significant (</offsets><italic><offsets xml_i="24842" xml_f="24843" txt_i="15911" txt_f="15912">P</offsets></italic><offsets xml_i="24852" xml_f="24866" txt_i="15912" txt_f="15923"> &lt; 0.001) [</offsets><xref ref-type="fig" rid="F5"><offsets xml_i="24896" xml_f="24904" txt_i="15923" txt_f="15931">Figure 5</offsets></xref><offsets xml_i="24911" xml_f="24913" txt_i="15931" txt_f="15933">].</offsets></p><fig id="F4" position="float"><label><offsets xml_i="24954" xml_f="24962" txt_i="15934" txt_f="15942">Figure 4</offsets></label><caption><p><offsets xml_i="24982" xml_f="25045" txt_i="15942" txt_f="16005">Assessment of number of absent days due to infection or allergy</offsets></p></caption><graphic xlink:href="ASL-36-141-g007"></graphic></fig><fig id="F5" position="float"><label><offsets xml_i="25150" xml_f="25158" txt_i="16006" txt_f="16014">Figure 5</offsets></label><caption><p><offsets xml_i="25178" xml_f="25250" txt_i="16014" txt_f="16086">Number of participants absent due to infection/allergy related illnesses</offsets></p></caption><graphic xlink:href="ASL-36-141-g008"></graphic></fig></sec></sec><sec id="sec2-11"><title><offsets xml_i="25355" xml_f="25415" txt_i="16089" txt_f="16149">Assessment of energy, physical fitness, strength and stamina</offsets></title><p><offsets xml_i="25426" xml_f="25644" txt_i="16150" txt_f="16368">Though no significant difference was observed between the groups at 3 and 6 months follow up, CP group showed a better improvement in energy levels, physical fitness, strength and stamina as compared to control group [</offsets><xref ref-type="table" rid="T4"><offsets xml_i="25676" xml_f="25683" txt_i="16368" txt_f="16375">Table 4</offsets></xref><offsets xml_i="25690" xml_f="25692" txt_i="16375" txt_f="16377">].</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="25740" xml_f="25747" txt_i="16378" txt_f="16385">Table 4</offsets></label><caption><p><offsets xml_i="25767" xml_f="25827" txt_i="16385" txt_f="16445">Assessment of energy, physical fitness, strength and stamina</offsets></p></caption><graphic xlink:href="ASL-36-141-g009"></graphic></table-wrap><p><offsets xml_i="25905" xml_f="26372" txt_i="16446" txt_f="16913">In CP group, there were 12 participants who were dissatisfied (Very dissatisfied, somewhat dissatisfied, A little dissatisfied) with their energy level at the baseline visit, which was reduced to two participants at the end of three months. At the end of six months, there was no participant who was dissatisfied with energy levels in CP Group. In the control group, however, there was one participant left dissatisfied out of 15 at baseline at the end of six months.</offsets></p><p><offsets xml_i="26379" xml_f="26691" txt_i="16914" txt_f="17226">15 participants were dissatisfied with their physical fitness at the baseline visit in CP group; this was reduced to one participant at the end of three and six months. However, in control group one participant out of 16 at baseline was dissatisfied with his physical fitness participants at the end of 6 months.</offsets></p><p><offsets xml_i="26698" xml_f="27024" txt_i="17227" txt_f="17553">In CP group, 16 participants were dissatisfied with their strength at the baseline visit, which was reduced to one participant at the end of 3 months and none at the end of 6 months. In control group, however, one participant was left in dissatisfied out of 16 participants at baseline at the end of 6 months in control group.</offsets></p><p><offsets xml_i="27031" xml_f="27329" txt_i="17554" txt_f="17852">There were 14 participants who were dissatisfied with their stamina at the baseline visit in CP group, which was reduced to one participant at the end of 3 months and none at the end of 6 months. In control group, there was no dissatisfied participant out of 14 at baseline at the end of 6 months [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="27361" xml_f="27368" txt_i="17852" txt_f="17859">Table 5</offsets></xref><offsets xml_i="27375" xml_f="27377" txt_i="17859" txt_f="17861">].</offsets></p><table-wrap id="T5" position="float"><label><offsets xml_i="27425" xml_f="27432" txt_i="17862" txt_f="17869">Table 5</offsets></label><caption><p><offsets xml_i="27452" xml_f="27559" txt_i="17869" txt_f="17976">Assessment of number of participants showing change in energy level, physical fitness, strength and stamina</offsets></p></caption><graphic xlink:href="ASL-36-141-g010"></graphic></table-wrap></sec><sec id="sec2-12"><title><offsets xml_i="27665" xml_f="27729" txt_i="17978" txt_f="18042">Assessment of quality of life through KIDSCREEN-27 Questionnaire</offsets></title><p><offsets xml_i="27740" xml_f="28002" txt_i="18043" txt_f="18305">Assessment of Quality of life through KIDSCREEN-27 Questionnaire over a period of 6 months showed an improvement in the domain score of “Physical Activity and Health” and “General Mood and Child's Feeling” in both the groups at the end of 6 months of the study [</offsets><xref ref-type="table" rid="T6"><offsets xml_i="28034" xml_f="28041" txt_i="18305" txt_f="18312">Table 6</offsets></xref><offsets xml_i="28048" xml_f="28214" txt_i="18312" txt_f="18478">]. As per one previously conducted survey on children, KIDSCREEN QOL-27 health questionnaire has been found to be a valid tool for accessing child's quality of life.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="28248" xml_f="28250" txt_i="18478" txt_f="18480">12</offsets></xref><offsets xml_i="28257" xml_f="28258" txt_i="18480" txt_f="18481">]</offsets></p><table-wrap id="T6" position="float"><label><offsets xml_i="28306" xml_f="28313" txt_i="18482" txt_f="18489">Table 6</offsets></label><caption><p><offsets xml_i="28333" xml_f="28407" txt_i="18489" txt_f="18563">Assessment of change in quality of life through KIDSCREEN-27 questionnaire</offsets></p></caption><graphic xlink:href="ASL-36-141-g011"></graphic></table-wrap></sec><sec id="sec2-13"><title><offsets xml_i="28513" xml_f="28554" txt_i="18565" txt_f="18606">Assessment of participants on CGI-I scale</offsets></title><p><offsets xml_i="28565" xml_f="28748" txt_i="18607" txt_f="18790">Assessment of participants on CGI-I scale showed that a higher percentage of participants (66.12%) showed improvement on this scale in CP Group as compared to control group (51.43%) [</offsets><xref ref-type="table" rid="T7"><offsets xml_i="28780" xml_f="28787" txt_i="18790" txt_f="18797">Table 7</offsets></xref><offsets xml_i="28794" xml_f="28796" txt_i="18797" txt_f="18799">].</offsets></p><table-wrap id="T7" position="float"><label><offsets xml_i="28844" xml_f="28851" txt_i="18800" txt_f="18807">Table 7</offsets></label><caption><p><offsets xml_i="28871" xml_f="28939" txt_i="18807" txt_f="18875">Physician's global evaluation for overall improvement on CGI-I scale</offsets></p></caption><graphic xlink:href="ASL-36-141-g012"></graphic></table-wrap></sec><sec id="sec2-14"><title><offsets xml_i="29045" xml_f="29065" txt_i="18877" txt_f="18897">Assessment of Safety</offsets></title><sec id="sec3-4"><title><offsets xml_i="29097" xml_f="29159" txt_i="18898" txt_f="18960">Assessment of overall safety and tolerability as per physician</offsets></title><p><offsets xml_i="29170" xml_f="29390" txt_i="18961" txt_f="19181">Assessment of overall safety by the physician showed that of the total 313 participants who were in the CP group, 92.45% showed excellent safety while the remaining 7.55% participants showed good or fair overall safety [</offsets><xref ref-type="table" rid="T8"><offsets xml_i="29422" xml_f="29429" txt_i="19181" txt_f="19188">Table 8</offsets></xref><offsets xml_i="29436" xml_f="29438" txt_i="19188" txt_f="19190">].</offsets></p><table-wrap id="T8" position="float"><label><offsets xml_i="29486" xml_f="29493" txt_i="19191" txt_f="19198">Table 8</offsets></label><caption><p><offsets xml_i="29513" xml_f="29591" txt_i="19198" txt_f="19276">Assessment of overall safety and tolerability of cyavanaprāśa as per physician</offsets></p></caption><graphic xlink:href="ASL-36-141-g013"></graphic></table-wrap></sec></sec><sec id="sec2-15"><title><offsets xml_i="29703" xml_f="29765" txt_i="19279" txt_f="19341">Assessment of overall safety through adverse events monitoring</offsets></title><p><offsets xml_i="29776" xml_f="30157" txt_i="19342" txt_f="19723">Adverse events which were not related to infection or allergy were recorded separately as AE in both the groups. A total of 248 participants were reported to have AE of which 133 were in CP group and 115 in the Control group. A total of 599 AE were recorded in the study, 316 in CP group and 283 in Control Group. These AE were, however, not found to be related to the study drugs </offsets><italic><offsets xml_i="30165" xml_f="30168" txt_i="19723" txt_f="19726">i.e</offsets></italic><offsets xml_i="30177" xml_f="30606" txt_i="19726" txt_f="20155">. there were no Adverse Drug Reaction in any participant. Fourteen events were assessed and reported as SAE, of which 6 were in CP group and 8 were from Control Group. None of the SAE's was related to the study drug or procedure. Assessment of vitals such as pulse, respiration and body temperature did not show any significant difference either within or between the groups. The study drug was well tolerated by the participant.</offsets></p></sec></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="30668" xml_f="30678" txt_i="20158" txt_f="20168">Discussion</offsets></title><p><offsets xml_i="30689" xml_f="30814" txt_i="20169" txt_f="20294">In recent times, CP has gained immense popularity all over the world as a time-tested immunity booster. Various pre-clinical[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="30848" xml_f="30850" txt_i="20294" txt_f="20296">13</offsets></xref><xref rid="ref14" ref-type="bibr"><offsets xml_i="30891" xml_f="30893" txt_i="20296" txt_f="20298">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="30934" xml_f="30936" txt_i="20298" txt_f="20300">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="30977" xml_f="30979" txt_i="20300" txt_f="20302">16</offsets></xref><xref rid="ref17" ref-type="bibr"><offsets xml_i="31020" xml_f="31022" txt_i="20302" txt_f="20304">17</offsets></xref><offsets xml_i="31029" xml_f="31323" txt_i="20304" txt_f="20598">] and clinical studies have been conducted to evaluate its safety and efficacy. Efficacy of CP in term of anti-allergic property, activity of Natural Killer (NK) cells and phagocytic activity, level of Tumor Necrosis Factor- alpha (TNF-a), IL- 1-b and MIP-1- a secreted by Dendritic Cells (DC,[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="31357" xml_f="31359" txt_i="20598" txt_f="20600">14</offsets></xref><offsets xml_i="31366" xml_f="31508" txt_i="20600" txt_f="20742">] improvement of quality of life in patient with recurrent cough and cold and health benefits under seasonal variations has been established.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="31541" xml_f="31542" txt_i="20742" txt_f="20743">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="31582" xml_f="31583" txt_i="20743" txt_f="20744">9</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="31624" xml_f="31626" txt_i="20744" txt_f="20746">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="31667" xml_f="31669" txt_i="20746" txt_f="20748">19</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="31710" xml_f="31712" txt_i="20748" txt_f="20750">20</offsets></xref><offsets xml_i="31719" xml_f="31720" txt_i="20750" txt_f="20751">]</offsets></p><p></p><p><offsets xml_i="31734" xml_f="31919" txt_i="20753" txt_f="20938">Demography parameters analysis showed that age and gender were equally represented in both groups. The Prakṛti classification of the majority of participants enrolled in the study were </offsets><italic><offsets xml_i="31927" xml_f="31950" txt_i="20938" txt_f="20961">Pitta-Kapha, Pitta-Vāta</offsets></italic><offsets xml_i="31959" xml_f="31964" txt_i="20961" txt_f="20966"> and </offsets><italic><offsets xml_i="31972" xml_f="31983" txt_i="20966" txt_f="20977">Kapha-Pitta</offsets></italic><offsets xml_i="31992" xml_f="32055" txt_i="20977" txt_f="21040"> which were almost equally distributed in CP and control group.</offsets></p><p><offsets xml_i="32062" xml_f="32607" txt_i="21041" txt_f="21586">In the current study, CP significantly improved the immunity of school going children. The study was conducted from the month of Mar 2015 to Feb 2016 which covered one summer, one rainy and one winter season. It showed that the children were protected from various illnesses related to infection or allergy under the different seasonal variations though out the year. These findings are also in consensus with earlier published literature which demonstrated that CP provides protection from various illnesses irrespective of seasonal influence.[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="32641" xml_f="32643" txt_i="21586" txt_f="21588">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="32684" xml_f="32686" txt_i="21588" txt_f="21590">19</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="32727" xml_f="32729" txt_i="21590" txt_f="21592">20</offsets></xref><offsets xml_i="32736" xml_f="32737" txt_i="21592" txt_f="21593">]</offsets></p><p><offsets xml_i="32744" xml_f="32945" txt_i="21594" txt_f="21795">Out of a total of 1255 episodes related to immunity related infections or allergies, control group had 2.10 times more number of episodes in comparison to CP group which was statistically significant (</offsets><italic><offsets xml_i="32953" xml_f="32954" txt_i="21795" txt_f="21796">P</offsets></italic><offsets xml_i="32963" xml_f="33177" txt_i="21796" txt_f="22007"> &lt; 0.01). Out of the total duration 3983 days of all episodes, the duration of such illness days was 1.91 times lesser in the CP group as compared to control group and was found to be statistically significant (</offsets><italic><offsets xml_i="33185" xml_f="33186" txt_i="22007" txt_f="22008">P</offsets></italic><offsets xml_i="33195" xml_f="33531" txt_i="22008" txt_f="22341"> &lt; 0.01). 540 participants were found to be affected by various illnesses related to infection or allergy and 87 participants did not have any such episode. The number of children having no immunity related illnesses was 2.22 times higher in the CP group as compared to control group which was found to be statistically significant (</offsets><italic><offsets xml_i="33539" xml_f="33540" txt_i="22341" txt_f="22342">P</offsets></italic><offsets xml_i="33549" xml_f="33741" txt_i="22342" txt_f="22531"> &lt; 0.01). Out of the total absent days from school, 2.27 times higher number of days were observed in the control group in comparison to CP group and found to be statistically significant (</offsets><italic><offsets xml_i="33749" xml_f="33750" txt_i="22531" txt_f="22532">P</offsets></italic><offsets xml_i="33759" xml_f="33958" txt_i="22532" txt_f="22728"> &lt; 0.001) as well. Out of the total participants who were absent from school due to such illness, 2.02 times more were observed in the control group and was found to be statistically significant (</offsets><italic><offsets xml_i="33966" xml_f="33967" txt_i="22728" txt_f="22729">P</offsets></italic><offsets xml_i="33976" xml_f="33989" txt_i="22729" txt_f="22739"> &lt; 0.001).</offsets></p><p><offsets xml_i="33996" xml_f="34247" txt_i="22740" txt_f="22991">These above mentioned effects are most likely related to the immune boosting potential of CP. The mechanism of these benefits of CP can be explained with the help of previously published literature and studies conducted on CP. CP has demonstrated the </offsets><italic><offsets xml_i="34255" xml_f="34263" txt_i="22991" txt_f="22999">in vitro</offsets></italic><offsets xml_i="34272" xml_f="34614" txt_i="22999" txt_f="23341"> immune boosting potential by various mechanisms. In the concentration range of 20 μg/ml – 500 μg/ml, CP was found to increase the activity of NK cells by 1.8 to 10.3 fold, levels of TNF-α, IL- 1-β and MIP-1- α secreted by DCs were found to be increased by 1.3 to 3.2 fold and phagocytic activity was found to be increased by 28.9% to 65.2%.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="34648" xml_f="34650" txt_i="23341" txt_f="23343">13</offsets></xref><xref rid="ref14" ref-type="bibr"><offsets xml_i="34691" xml_f="34693" txt_i="23343" txt_f="23345">14</offsets></xref><offsets xml_i="34700" xml_f="34718" txt_i="23345" txt_f="23363">] In two separate </offsets><italic><offsets xml_i="34726" xml_f="34733" txt_i="23363" txt_f="23370">in-vivo</offsets></italic><offsets xml_i="34742" xml_f="34929" txt_i="23370" txt_f="23557"> studies, the level of IgE and plasma histamine were observed to be almost equal to the vehicle when challenged with allergens in animals (mice and rats respectively) pretreated with CP.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="34963" xml_f="34965" txt_i="23557" txt_f="23559">21</offsets></xref><offsets xml_i="34972" xml_f="35115" txt_i="23559" txt_f="23702">] These two studies are suggestive of suppression of allergic response in response to allergens implying protection against various infections.</offsets></p><p><offsets xml_i="35122" xml_f="35238" txt_i="23703" txt_f="23819">Studies on CP have indicated that it contains a number of phenolics which may account for its therapeutic activity.[</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="35272" xml_f="35274" txt_i="23819" txt_f="23821">22</offsets></xref><offsets xml_i="35281" xml_f="35346" txt_i="23821" txt_f="23886">] CP also contains honey which works as ‘a carrier of herbs’, or </offsets><italic><offsets xml_i="35354" xml_f="35362" txt_i="23886" txt_f="23894">Yogavāhī</offsets></italic><offsets xml_i="35371" xml_f="35491" txt_i="23894" txt_f="24014">, thereby potentiates absorption of various herbs deep into the tissues and imparts youth, charm, vigour and longevity.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="35524" xml_f="35525" txt_i="24014" txt_f="24015">7</offsets></xref><offsets xml_i="35532" xml_f="36284" txt_i="24015" txt_f="24767">] In the current study as well, the subject diaries were evaluated to assess the change in energy, physical fitness, strength and stamina. Under all of these parameters, fair amounts of improvement were observed at end of three months that continued until the end of the study in both groups. The improvement was higher in CP group in comparison to control. However, comparison within and between the groups was not statistically significant. Assessment of above mentioned parameters in terms of number of children revealed that in CP group all participants except one, moved from the category of dissatisfied to satisfied at the end of the study in comparison to control where 4 participants were still in category of dissatisfied at the end of study.</offsets></p><p><offsets xml_i="36291" xml_f="37267" txt_i="24768" txt_f="25740">Assessment of Quality of life through KIDSCREEN-27 Questionnaires showed improvement in the domain score of “Physical Activity and Health” and “General Mood and Child's Feeling” in both the groups at the end of 6 months of the study. The domain score of “Physical Activity and Health” in CP as well as in control group improved from baseline to the end of the study and was found to be significant. The improvement in this domain was however found to be higher in CP group however; there was no significant difference between the two groups. Similarly the “general mood and child's feeling” showed a better improvement in CP group as compared to control group over 6 months period. The domain score of ‘School &amp; learning’ showed a significant improvement in both the groups from one month further to 3 months and 6 months. The other domains of ‘Family and child's free time and Friends’ did not show any significant change both within the group and between the two groups.</offsets></p><p><offsets xml_i="37274" xml_f="37799" txt_i="25741" txt_f="26266">Assessment of participants on CGI-I scale showed that a higher percentage of participants showed improvement on this scale in CP group as compared to control group. Assessment of overall safety by the physician showed that of the total 313 participants in CP group, 92.45% of the participants showed excellent safety while the remaining 7.55% participants showed good or fair overall safety. All reported AEs and SAEs were found to be not related to the study drugs. Assessment of vitals did not show any significant finding.</offsets></p><p><offsets xml_i="37806" xml_f="38261" txt_i="26267" txt_f="26722">As per earlier published literature as well, CP was found to be safe in the recommended dosage for the defined period of time in toxicity studies. In all the toxicity studies i.e. acute dose oral toxicity, 28 days repeated dose oral toxicity studies and in the 90 days repeated dose oral toxicity studies, CP did not cause any signs of toxicity, body weight loss with all animals surviving throughout the study periods. In acute oral dose toxicity, the LD</offsets><sub><offsets xml_i="38266" xml_f="38268" txt_i="26722" txt_f="26724">50</offsets></sub><offsets xml_i="38274" xml_f="38512" txt_i="26724" txt_f="26962"> value of CP in both sexes of rats and mice was found to be greater than 2000 mg/kg of the body weight. The no observed adverse effect level (NOAEL) of CP was found to be 1000 mg/Kg body weight in both 28 day and 90 day toxicity studies.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="38546" xml_f="38548" txt_i="26962" txt_f="26964">13</offsets></xref><offsets xml_i="38555" xml_f="38556" txt_i="26964" txt_f="26965">]</offsets></p><p><offsets xml_i="38563" xml_f="38728" txt_i="26966" txt_f="27131">The results of the above study on immunity related benefits of CP and safety parameters appear to be in line with the earlier studies and published data on the same.</offsets></p></sec><sec sec-type="conclusion" id="sec1-5"><title><offsets xml_i="38784" xml_f="38794" txt_i="27133" txt_f="27143">Conclusion</offsets></title><p><offsets xml_i="38805" xml_f="40453" txt_i="27144" txt_f="28792">The present study concluded that regular consumption of CP for a period of three to six months helps to improve immunity, energy levels, physical fitness, strength, stamina and quality of life of children as assessed by various parameters. The primary parameter of immunity (episodes of infections or allergy related conditions) showed more than 2 times protection from illness in CP group as compared to the control group. The duration of illness related to infection or allergy was also observed to be significantly lesser in CP group as compared to control group. Other parameters of assessment of immunity such as number of absent days and number of absent participants in school due to these illnesses, also confirmed that CP showed more than twice the protection from immunity related illness as compared to the control group. There was a significant change in energy levels, physical fitness levels, strength and stamina in both the groups, however, CP showed better percentage improvement on these parameters as compared to the control group. Assessment of quality of life by KIDSCREEN-27 Questionnaire showed better improvement in CP group as compared to control group on domains of “Physical activity and Health”, “General Mood and Child's Feelings” and “School and learning.” Assessment of overall improvement by the physician (CGI-I) also showed that over a period of 6 months more number of participants improved in CP group as compared to control group. CP showed excellent to good safety in all the participants in the study. No Adverse events/Serious Adverse events reported was assessed to be related to study product or procedure.</offsets></p><sec id="sec2-16"><title><offsets xml_i="40482" xml_f="40515" txt_i="28793" txt_f="28826">Financial support and sponsorship</offsets></title><p><offsets xml_i="40526" xml_f="40656" txt_i="28827" txt_f="28957">The study was sponsored by Dabur Research and Development Centre, Dabur India Limited, Sahibabad (Ghaziabad) Uttar Pradesh, India.</offsets></p></sec><sec id="sec2-17" sec-type="COI-statement"><title><offsets xml_i="40716" xml_f="40737" txt_i="28959" txt_f="28980">Conflicts of interest</offsets></title><p><offsets xml_i="40748" xml_f="40857" txt_i="28981" txt_f="29090">Some of the Authors (Arun Gupta, Sunil Kumar and V. Sasibhushan) are currently employed with Dabur India Ltd.</offsets></p></sec></sec></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grüber</surname><given-names>C</given-names></name><name><surname>Keil</surname><given-names>T</given-names></name><name><surname>Kulig</surname><given-names>M</given-names></name><name><surname>Roll</surname><given-names>S</given-names></name><name><surname>Wahn</surname><given-names>U</given-names></name><name><surname>Wahn</surname><given-names>V</given-names></name></person-group><collab>MAS-Study Group</collab><article-title>History of respiratory infections in the first 12 yr among children from a birth cohort</article-title><source>Pediatr Allergy Immunol</source><year>2008</year><volume>19</volume><fpage>505</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18167154</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhater</surname><given-names>SA</given-names></name></person-group><article-title>Approach to the child with recurrent infections</article-title><source>J Family Community Med</source><year>2009</year><volume>16</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">23012196</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="webpage"><article-title>The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Centers for Disease Control and Prevention (US)</article-title><year>2006</year><date-in-citation>Last accessed on 2016 Dec 23</date-in-citation><comment>Available from:
<uri xlink:type="simple" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK44318/">https://www.ncbi.nlm.nih.gov/books/NBK44318/</uri></comment></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuzil</surname><given-names>KM</given-names></name><name><surname>Hohlbein</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group><article-title>Illness among schoolchildren during influenza season: Effect on school absenteeism, parental absenteeism from work, and secondary illness in families</article-title><source>Arch Pediatr Adolesc Med</source><year>2002</year><volume>156</volume><fpage>986</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12361443</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Henman</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>K</given-names></name><name><surname>Fahey</surname><given-names>T</given-names></name></person-group><article-title>Over-the-counter cough medicines in children: Neither safe or efficacious?</article-title><source>Br J Gen Pract</source><year>2008</year><volume>58</volume><fpage>757</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19000398</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Sastry</surname><given-names>K</given-names></name><name><surname>Chaturvedi</surname><given-names>G</given-names></name></person-group><source>Charak Samhita of Angnivesa. Chikitsasthana: Divitiya Rasayana Prakran Adhyay</source><year>Reprint 2011</year><volume>2</volume><issue>Ch. 2, Ver. 70-74</issue><publisher-loc>Varanasi, India</publisher-loc><publisher-name>Chaukhambha Bharati Academy</publisher-name><fpage>16</fpage><lpage>7</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parle</surname><given-names>M</given-names></name><name><surname>Bansal</surname><given-names>N</given-names></name></person-group><article-title>Traditional medicinal formulation, Chyawanprash – A review</article-title><source>Indian J Tradit Knowl</source><year>2006</year><volume>5</volume><fpage>484</fpage><lpage>8</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode</surname><given-names>M</given-names></name></person-group><article-title>Assembling cyavanaprash, Ayurveda's best-selling medicine</article-title><source>Anthropol Med</source><year>2015</year><volume>22</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">25639150</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayana</surname><given-names>DB</given-names></name><name><surname>Durg</surname><given-names>S</given-names></name><name><surname>Manohar</surname><given-names>PR</given-names></name><name><surname>Mahapatra</surname><given-names>A</given-names></name><name><surname>Aramya</surname><given-names>AR</given-names></name></person-group><article-title>Chyawanprash: A review of therapeutic benefits as in authoritative texts and documented clinical literature</article-title><source>J Ethnopharmacol</source><year>2017</year><volume>197</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">27496580</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized studys</article-title><source>Ann Intern Med</source><year>2001</year><volume>134</volume><fpage>657</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11304106</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="book"><source>Rasa Tantra Sara Siddha Prayog Sangraha. Pratham Khanda. Krishan-Gopal Ayurveda Bhawan</source><year>1961</year><edition>9th ed</edition><publisher-loc>Ajmer</publisher-loc><publisher-name>Kaleda-Krishangopal</publisher-name><fpage>779</fpage><lpage>83</lpage></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravens-Sieberer</surname><given-names>U</given-names></name><name><surname>Herdman</surname><given-names>M</given-names></name><name><surname>Devine</surname><given-names>J</given-names></name><name><surname>Otto</surname><given-names>C</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The European KIDSCREEN approach to measure quality of life and well-being in children: Development, current application, and future advances</article-title><source>Qual Life Res</source><year>2014</year><volume>23</volume><fpage>791</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">23686556</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>JLN</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Brindavanam</surname><given-names>NB</given-names></name><name><surname>Kanjilal</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Quantification of immunity status of Dabur Chyawanprash – A review part-1 (Experimental Studies)</article-title><source>Indian J Appl Res</source><year>2014</year><volume>4</volume><fpage>20</fpage><lpage>4</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madaan</surname><given-names>A</given-names></name><name><surname>Kanjilal</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Sastry</surname><given-names>JL</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>AT</given-names></name><etal></etal></person-group><article-title>Evaluation of immunostimulatory activity of Chyawanprash using <italic>in vitro</italic> assays</article-title><source>Indian J Exp Biol</source><year>2015</year><volume>53</volume><fpage>158</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">25872246</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parle</surname><given-names>M</given-names></name><name><surname>Bansal</surname><given-names>N</given-names></name></person-group><article-title>Antiamnesic activity of an ayurvedic formulation chyawanprash in mice</article-title><source>Evid Based Complement Alternat Med 2011</source><year>2011</year><fpage>898593</fpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>N</given-names></name><name><surname>Parle</surname><given-names>M</given-names></name></person-group><article-title>Beneficial effect of chyawanprash on cognitive function in aged mice</article-title><source>Pharm Biol</source><year>2011</year><volume>49</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20738179</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manjunatha</surname><given-names>S</given-names></name><name><surname>Jaryal</surname><given-names>AK</given-names></name><name><surname>Bijlani</surname><given-names>RL</given-names></name><name><surname>Sachdeva</surname><given-names>U</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name></person-group><article-title>Effect of Chyawanprash and Vitamin C on glucose tolerance and lipoprotein profile</article-title><source>Indian J Physiol Pharmacol</source><year>2001</year><volume>45</volume><fpage>71</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11211574</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>JL</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Brindavanam</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Quantification of immunity status of Dabur Chyawanprash – A review part-2 (Clinical Studies)</article-title><source>Indian J Appl Res</source><year>2014</year><volume>4</volume><fpage>205</fpage><lpage>11</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uma</surname><given-names>A</given-names></name><name><surname>Pajanivel</surname><given-names>R</given-names></name><name><surname>Raj</surname><given-names>S</given-names></name><name><surname>Lokeshmaran</surname></name></person-group><article-title>Smoking-induced satellite associations in a rural population of south India: An <italic>in vitro</italic> study</article-title><source>Int J Appl Basic Med Res</source><year>2011</year><volume>1</volume><fpage>75</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23776781</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>SS</given-names></name><name><surname>Archana</surname><given-names>R</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Symphoria</surname></name><name><surname>Mukkadan</surname><given-names>JK</given-names></name></person-group><article-title>Effect of Chyawanprash on cognitive, autonomic and respiratory parameters in college students</article-title><source>Int J Res Ayurveda Pharm</source><year>2014</year><volume>5</volume><fpage>435</fpage><lpage>8</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Bhat</surname><given-names>TA</given-names></name><name><surname>Madaan</surname><given-names>A</given-names></name></person-group><article-title>Determination of anti-allergic potential of DRDC/AY/8044 (Dabur Chyawanprash) by estimation of levels of histamine in plasma of Wistar rats. Data on files</article-title><year>2010</year><publisher-loc>New Delhi</publisher-loc><publisher-name>Althea Lifesciences Limited</publisher-name><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindarajan</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>DP</given-names></name><name><surname>Rawat</surname><given-names>AK</given-names></name></person-group><article-title>High-performance liquid chromatographic method for the quantification of phenolics in 'Chyavanprash'a potent Ayurvedic drug</article-title><source>J Pharm Biomed Anal</source><year>2007</year><volume>43</volume><fpage>527</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16971083</pub-id></element-citation></ref></ref-list></back></article>